The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IV and Recurrent Rectal Cancer

Added text about the Crystal Study that randomly assigned patients to FOLFIRI with or without cetuximab (cited Van Cutsem et al. as reference 47 and level of evidence 1iiDii).

Added text about patients with mutant KRAS tumors who may experience worse outcome when cetuximab is added to multiagent chemotherapy regimens containing bevacizumab.

Back to Top

< Previous Section  |  Next Section >